Biogen Secures Global Rights to Vanqua Bio's C5aR1 Program in $70 Million Deal
Biogen Inc. has secured exclusive global rights to Vanqua Bio's preclinical C5aR1 antagonist through a $70 million license agreement. Vanqua will receive the upfront payment and could earn up to $990 million in additional milestone payments, along with tiered royalties on net sales. Biogen will handle all future development and commercialization activities for the program, with the upfront payment recorded as an Acquired In-Process Research and Development expense in Q4 2025.
Biogen Inc. has announced a license agreement with Vanqua Bio, granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. Under the terms of the agreement, Vanqua will receive a $70 million upfront payment and is eligible for up to $990 million in potential development, regulatory, commercial, and sales milestone payments, as well as tiered royalties on potential net sales. Biogen will assume responsibility for all future development, manufacturing, and commercialization activities related to the program. The upfront payment will be recorded by Biogen as an Acquired In-Process Research and Development expense in the fourth quarter of 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551388-en) on October 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
